North America Nicotine Replacement Therapy Market Size & Outlook
North America nicotine replacement therapy market, 2018-2030 (US$M)
North America nicotine replacement therapy market highlights
- The North America nicotine replacement therapy market generated a revenue of USD 17,506.3 million in 2023.
- The market is expected to grow at a CAGR of 13.1% from 2024 to 2030.
- In terms of segment, nicotine replacement therapy was the largest revenue generating product in 2023.
- Nicotine Replacement Therapy is the most lucrative product segment registering the fastest growth during the forecast period.
North America data book summary
| Market revenue in 2023 | USD 17,506.3 million |
| Market revenue in 2030 | USD 41,468.7 million |
| Growth rate | 13.1% (CAGR from 2023 to 2030) |
| Largest segment | Nicotine replacement therapy |
| Fastest growing segment | Nicotine Replacement Therapy |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Nicotine Replacement Therapy |
| Key market players worldwide | Cipla Ltd DR, Pfizer Inc, Philip Morris International Inc, British American Tobacco, Japan Tobacco Inc, Imperial Brands PLC, Johnson & Johnson |
Other key industry trends
- In terms of revenue, North America region accounted for 25.3% of the global nicotine replacement therapy market in 2023.
- Globally, Asia Pacific is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 99,743.2 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Nicotine Replacement Therapy Market Scope
Nicotine Replacement Therapy Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
North America nicotine replacement therapy market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to nicotine replacement therapy market will help companies and investors design strategic landscapes.
Nicotine replacement therapy was the largest segment with a revenue share of 100% in 2023. Horizon Databook has segmented the North America nicotine replacement therapy market based on nicotine replacement therapy covering the revenue growth of each sub-segment from 2018 to 2030.
Growth of NRT market in North America can be attributed to various factors, including the growing burden of diseases associated with smoking and the increase in number of favorable government initiatives. Moreover, increasing adoption of e-cigarettes and heated tobacco products is expected to positively impact North America’s nicotine replacement therapy market.
The major tobacco companies in North America are focusing on product launches. Two of the major players operating in this market are GlaxoSmithKline plc. and Philip Morris Products S.A. The local presence globally leading companies is expected to increase the availability of alternatives in the region.
The presence of highly influential regulatory entities in North American countries is expected to foster the development of novel treatments in the near future. This is mainly due to the fact that these entities play a pivotal role in creating awareness among the people about the potential of treatments and supportive care in the management of smoking cessation.
Reasons to subscribe to North America nicotine replacement therapy market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of North America nicotine replacement therapy market databook
-
Our clientele includes a mix of nicotine replacement therapy market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America nicotine replacement therapy market , including forecasts for subscribers. This continent databook contains high-level insights into North America nicotine replacement therapy market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
